Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antiestrogens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Antiestrogens. Displaying page 1 of 1.
    EudraCT Number: 2013-001010-14 Sponsor Protocol Number: XL184-308 Start Date*: 2013-08-15
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) BE (Completed) CZ (Completed) PT (Completed) IE (Completed) IT (Completed) NL (Completed) SK (Completed) GB (Completed) ES (Completed) DE (Completed) DK (Completed) FR (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004991-20 Sponsor Protocol Number: ACTION Start Date*: 2020-04-28
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: A phase II triAl of Cabozantinib for hepaTocellular carcInoma patients intOlerant to sorafenib treatment or first line treatment different to sorafeNib. (ACTION trial)
    Medical condition: Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-001001-91 Sponsor Protocol Number: XL184-309 Start Date*: 2013-08-12
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib.
    Medical condition: Subjects with Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed) NL (Ongoing) ES (Completed) IE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012964-14 Sponsor Protocol Number: XL184-203 Start Date*: 2010-03-10
    Sponsor Name:Exelixis Inc
    Full Title: A randomized discontinuation study of XL184 in subjects with advanced solid tumors
    Medical condition: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004098-23 Sponsor Protocol Number: Tide-A Start Date*: 2020-06-18
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002860-29 Sponsor Protocol Number: ONC-2019-002 Start Date*: 2019-12-12
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo).
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005504-28 Sponsor Protocol Number: EORTC-1525-LCG Start Date*: 2017-12-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
    Medical condition: type B3 thymoma and thymic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061031 Thymoma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) NL (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002887-42 Sponsor Protocol Number: EORTC-1612-MG Start Date*: 2018-06-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresect...
    Medical condition: BRAF V600 mutation–positive unresectable or metastatic melanoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003680-35 Sponsor Protocol Number: 1652-CLTF Start Date*: 2019-01-31
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)
    Medical condition: Subtypes of Cutaneous T cell ltymphoma (CTCL): Mycosis Fungoides (MF) and Sézary Syndrome (SS)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028508 Mycosis fungoides/Sezary syndrome LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028483 Mycosis fungoides LLT
    20.0 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10040785 - Skin and subcutaneous tissue disorders 10042356 Skin and subcutaneous conditions NEC HLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040790 Skin and subcutaneous tissue disorders NEC HLGT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016862-10 Sponsor Protocol Number: XL147-203 Start Date*: 2010-06-22
    Sponsor Name:Exelixis INC.
    Full Title: A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based ...
    Medical condition: Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab-Based Regimen
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000053-53 Sponsor Protocol Number: EORTC-1714-ROG-GITCG Start Date*: 2018-11-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)
    Medical condition: oesophageal squamous cell carcinoma and oeasophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006140-78 Sponsor Protocol Number: TED12414 Start Date*: 2012-03-15
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a mon...
    Medical condition: Neoplasm malignant
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023550-36 Sponsor Protocol Number: H8Y-MC-HBDE Start Date*: 2011-04-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Completed) PL (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 17:00:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA